• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

5 months ago
Deals
R&D

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

5 months ago
R&D
Cell/Gene Tx

The End­points 100 is back; In­side Iso­mor­phic Labs; FDA ad­comm dis­cuss­es se­vere RSV cas­es; and more

5 months ago
Weekly

FTC OKs No­vo-Catal­ent deal in ma­jor win for No­vo Nordisk’s GLP-1 man­u­fac­tur­ing

5 months ago
Deals
Manufacturing

Organon's steroid-free cream Vta­ma wins ap­proval in atopic der­mati­tis

5 months ago
Pharma
FDA+

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

5 months ago
Pharma
Law

FDA stands by mifepri­s­tone safe­ty la­bel in fed­er­al court chal­lenge

5 months ago
Pharma
FDA+

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

5 months ago
R&D
Pharma

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

5 months ago
Pharma
FDA+

Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

5 months ago
People
R&D

BeiGene li­cens­es sol­id tu­mor drug, match­es with Ideaya’s com­bo plans

5 months ago
Deals
R&D

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

5 months ago
R&D
Pharma

Re­pare plans for Phase 3 en­dome­tri­al can­cer study, sidelin­ing ovar­i­an can­cer

5 months ago
R&D

Ei­sai sub­sidiary nabs Japan rights for schiz­o­phre­nia drug; No­vavax's $50M mile­stone

5 months ago
News Briefing

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

5 months ago
Startups
Deals

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

5 months ago
People
Peer Review

Af­ter poor lung can­cer da­ta, iTeos drops in­u­padenant to dou­ble down on TIG­IT

5 months ago
R&D

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

5 months ago
People

Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

5 months ago
R&D
Cell/Gene Tx

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

5 months ago
R&D
Pharma

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

5 months ago
Pharma
FDA+

Hand­ful of 'un­sup­port­ed' drug price in­creas­es added $800M to US costs, ICER claims

5 months ago
Pharma

Pad­lock share­hold­ers sue Bris­tol My­ers over mile­stone dis­pute af­ter 2016 ac­qui­si­tion

5 months ago
Deals
Pharma

El­e­va­tion to pay up to $368M in ADC deal; Bavar­i­an Nordic clos­es San Diego site

5 months ago
News Briefing
First page Previous page 64656667686970 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times